🇺🇸 Cisplatin + Gemcitabine in United States

59 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 59

Most-reported reactions

1. Off Label Use — 11 reports (18.64%)
2. Malignant Neoplasm Progression — 8 reports (13.56%)
3. Thrombocytopenia — 8 reports (13.56%)
4. Therapy Non-Responder — 6 reports (10.17%)
5. Anaemia — 5 reports (8.47%)
6. Disease Progression — 5 reports (8.47%)
7. Inappropriate Schedule Of Product Administration — 5 reports (8.47%)
8. Death — 4 reports (6.78%)
9. Mixed Hepatocellular Cholangiocarcinoma — 4 reports (6.78%)
10. Drug Resistance — 3 reports (5.08%)

Source database →

Frequently asked questions

Is Cisplatin + Gemcitabine approved in United States?

Cisplatin + Gemcitabine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Cisplatin + Gemcitabine in United States?

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is the originator. The local marketing authorisation holder may differ — check the official source linked above.